Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

45.52 +0.09 (+0.20%)

Streaming Delayed Price Updated: 3:59 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

33 34 Next >

Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover ↗

July 14, 2023

The report sent Roivant Sciences higher Friday, but a deal is far from guaranteed.

Via Investor's Business Daily

Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal ↗

July 14, 2023

Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY)

Via Benzinga

How Roche Just Cut Top 1% Biotech Stock TG Therapeutics Down A Peg ↗

July 13, 2023

The companies are rivals in the multiple sclerosis treatment realm with Ocrevus and Briumvi.

Via Investor's Business Daily

Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion ↗

July 13, 2023

Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with...

Via Benzinga

Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis

July 13, 2023

From Genentech

Via Business Wire

Stock Analysis: Roche Holding AG ↗

May 16, 2023

Roche is a Swiss biopharmaceutical and diagnostic company.

Via Talk Markets

Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal Muscular Atrophy (SMA) Able to Sit, Stand and Walk

June 30, 2023

From Genentech

Via Business Wire

Monkeypox Vaccine: Blue Water Biotech Touts Encouraging Preclinical Data From Monkeypox Vaccine Candidate ↗

June 28, 2023

Blue Water Biotech Inc (NASDAQ: BWV) has released preliminary preclinical data that supports the potential use of its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform for the...

Via Benzinga

Agilent Technologies Stock: Ready to Rise off the Floor

June 21, 2023

Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider.

Via MarketBeat

Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma ↗

June 16, 2023

The FDA approved Roche Holding AG's (OTC: RHHBY) Columvi (glofitamab-gxbm) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL)...

Via Benzinga

FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

June 15, 2023

From Genentech

Via Business Wire

EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035 ↗

June 14, 2023

JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) with a Buy rating and

Via Benzinga

New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control ↗

June 09, 2023

Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e

Via Benzinga

New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)

June 09, 2023

From Genentech

Via Business Wire

Why Shares of Zentalis Pharmaceuticals Dropped This Week ↗

June 02, 2023

A rash of insider selling meant the stock gave back some of its gains from last week.

Via The Motley Fool

Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class ↗

May 26, 2023

Roche tested its treatment in patients with liver cancer and found "meaningful" results.

Via Investor's Business Daily

Why Shares of Rain Oncology Are Plummeting Today ↗

May 22, 2023

The company released disappointing top-line results for its lead oncology therapy.

Via The Motley Fool

Apple Thwarts $2B In Fraud Transactions, UBS Takes $17B Hit From 'Hasty Credit Suisse Takeover,' Verizon Streamlines Unlimited Data Plans: Today's Top Stories ↗

May 17, 2023

Benzinga

Via Benzinga

Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows ↗

May 17, 2023

Roche Holdings AG's (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)

Via Benzinga

Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis

May 17, 2023

From Genentech

Via Business Wire

3 Stocks That Are Reshaping the Future ↗

May 16, 2023

As the population ages and AI develops, these three companies stand out among stocks reshaping the future.

Via InvestorPlace

Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy

May 16, 2023

Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock.

Via MarketBeat

Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC ↗

May 13, 2023

Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr....

Via Talk Markets

FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

May 09, 2023

From Genentech

Via Business Wire

Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales

May 05, 2023

Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.

Via MarketBeat

EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials ↗

May 04, 2023

SAB Biotherapeutics Inc (NASDAQ: SABS) has announced the presentation of safety and efficacy data from Phase 1 and 2a trials of its influenza immunotherapy, SAB-176.

Via Benzinga

Tempest Therapeutics' TPST-1120 Shines In Early Phase 1b/2 Study: Analysts Get Bullish ↗

April 28, 2023

Tempest Therapeutics Inc (NASDAQ: TPST) announced

Via Benzinga

Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost? ↗

April 27, 2023

The company reported lighter-than-expected declines due to Keytruda and Gardasil.

Via Investor's Business Daily

Roche's Q1 Highlights: Increased Uptake Of Eye Disease Drug Cushions Sales Decline ↗

April 26, 2023

Roche Holdings AG's (OTC: RHHBY) first-quarter sales dropped 7% Y/Y (down 3% at constant currency)

Via Benzinga

Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls ↗

April 26, 2023

Both GSK and Roche experienced declining Covid-related sales in the first quarter.

Via Investor's Business Daily

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.